Dariohealth Corp Stock Price, News & Analysis

DarioHealth (NASDAQ: DRIO) announced a strategic collaboration with OneStep on Oct 6, 2025 to integrate OneStep's FDA-listed smartphone-only clinical-grade fall risk assessment into Dario's multi-condition digital health platform. The parties signed a Memorandum of Understanding (MOU) and expect to finalize a Master Services Agreement in the coming weeks. The integration aims to identify fall risk among high-risk groups (including members with obesity and Medicare Advantage populations), improve engagement and independence, and drive measurable ROI for self-insured employers and health plans. The release cites falls as a >$50 billion annual direct medical cost and notes the US fall management market was ~$200 million in 2024, projected to exceed $300 million by 2033 (CAGR >5%).

DarioHealth (NASDAQ:DRIO), a digital health solutions provider for chronic condition management, has initiated a comprehensive strategic review following multiple unsolicited inquiries from interested parties. The company's Board has formed a Special Committee and engaged Perella Weinberg Partners as financial advisor to evaluate potential opportunities including a sale, merger, or strategic business combination.

In recent developments, Dario has completed an oversubscribed $17.5 million private placement, bringing its pro forma cash position to approximately $40 million as of Q2 2025. The company has also optimized its capital structure by converting outstanding preferred shares into common stock and equivalents, creating a more transparent equity structure.

DarioHealth (NASDAQ: DRIO), a global digital health market leader, has announced a $17.5 million private placement of common stock. The company will sell 2,713,180 shares at $6.45 per share, with the offering expected to close around September 23, 2025.

The private placement is being conducted under Section 4(a)(2) of the Securities Act and Regulation D, with the company committing to file a registration statement with the SEC for the resale of the shares. The proceeds will be used for general corporate purposes.

DarioHealth (NASDAQ: DRIO) released a shareholder update highlighting its strategic progress in the digital health market. The company's multi-condition platform addresses 5 chronic conditions including diabetes, hypertension, weight management, musculoskeletal, and behavioral health on a unified platform.

The company reported a commercial pipeline worth $67 million, supported by partnerships with TPAs and pharmacy managers representing 87 million member lives. Clinical studies demonstrate significant outcomes, including $5,000 annual payer savings per user, 23% reduction in hospitalizations, and 9% reduction in healthcare utilization.

DarioHealth (NASDAQ: DRIO) announced the successful launch of five new employer contracts, including its largest employer contract to date, covering 107,000 lives. The contracts, implemented during Q2 and Q3 2025, feature Dario's complete cardiometabolic suite.

The company's digital health solutions have demonstrated significant results: 23% reduction in hospitalizations, 9% reduction in healthcare utilization, and $5,000 reduction in employer costs per user. Clinical outcomes include a 1.4% reduction in eHbA1c for diabetes, 10% reduction in BMI for prediabetes, and 38% of users reducing blood pressure by one stage.

Dario maintains a robust pipeline of $67 million in commercial opportunities and targets approximately 40 new client signings by year-end 2025, representing a 35% increase over 2024.

DarioHealth (NASDAQ: DRIO), a digital health market leader, has announced a 20-for-1 reverse stock split effective August 28, 2025. The company's outstanding common stock will be reduced from 47,996,572 to approximately 2,399,829 shares.

The split was approved by DRIO's board of directors following stockholder authorization at the July 23, 2025 Annual Meeting. Trading will continue under the "DRIO" symbol but with a new CUSIP Number (23725P 308). The company's authorized shares remain at 400,000,000, and fractional shares will be rounded up to the nearest whole share per stockholder.

The reverse split will not materially affect stockholders' ownership percentages or voting power, and all options, convertible securities, restricted stocks, and warrants will be appropriately adjusted.

DarioHealth (NASDAQ: DRIO) reported Q2 2025 financial results with revenue of $5.4 million, down from $6.3 million in Q2 2024 and $6.8 million in Q1 2025. Despite the revenue decline, the company showed significant operational improvements with a 43% reduction in operating loss and a 36% decrease in operating expenses year-over-year.

The company secured 21 new clients year-to-date and reported approximately $5 million in new committed annual recurring revenues (CARR), with a robust pipeline of $53 million in commercial opportunities. Gross margin improved to 55% compared to 44% in Q2 2024, with B2B2C operations maintaining approximately 80% non-GAAP gross margins.

Due to implementation delays, Dario has adjusted its cashflow breakeven timeline by 12-15 months, now expected between late 2026 and early 2027.

DarioHealth (Nasdaq: DRIO), a leader in the global digital health market, will release its Q2 2025 financial results on Tuesday, August 12th, 2025. The company will host a conference call and webcast at 8:30 a.m. Eastern Time, before market opens.

The earnings call will be hosted by CEO Erez Raphael, President and CCO Steven Nelson, and CFO Chen Franco-Yehuda. Participants can join via dial-in numbers or through the Call me™ link, which will be active 15 minutes before the call. A replay will be available until August 26th, 2025.

DarioHealth (NASDAQ: DRIO) has announced a strategic commercial agreement with GreenKey Health to address the $150 billion sleep apnea market. The collaboration combines Dario's AI-powered cardiometabolic and behavioral health solutions with GreenKey's sleep-first approach to obstructive sleep apnea (OSA) management.

The partnership targets 29 million Americans affected by sleep apnea, with up to 80% of moderate to severe cases currently undiagnosed. The joint solution aims to improve member outcomes, reduce healthcare costs, and increase productivity through integrated behavioral health, sleep, and cardiometabolic care. The initiative will focus on engaging Commercial, ASO, Medicaid, Medicare Advantage plans, self-funded employers, and other healthcare stakeholders.